Lassa Fever Market was valued at USD 78 million in 2024 and is projected to reach USD 165 million by 2034

Market Overview
The Lassa Fever Market was valued at USD 78 million in 2024 and is projected to reach USD 165 million by 2034, growing at a CAGR of 7.7% during the forecast period.

Lassa fever is an acute viral hemorrhagic illness caused by the Lassa virus, primarily endemic in West Africa. Transmission occurs from rodents (Multimammate rats) to humans and via human-to-human spread in healthcare settings. The disease poses a significant public health challenge due to its high infection rates, severe complications, lack of approved vaccines, and frequent outbreaks.

Rising outbreak frequency, improved surveillance, increasing R&D investment in antiviral therapies and vaccines, and growing international support for epidemic preparedness are major contributors to market growth.

Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71747

Market Dynamics
Drivers
• Increasing incidence of Lassa fever outbreaks in endemic West African countries such as Nigeria, Sierra Leone, Liberia, and Guinea.
• Growing government and NGO-funded programs for viral hemorrhagic fever preparedness and control.
• Advancement in antiviral research, including ribavirin formulations and novel therapeutic agents.
• Strengthening of laboratory diagnostics and PCR testing capacity in Africa.
• International funding from WHO, CEPI, BARDA, and global health organizations supporting vaccine development.

Restraints
• Lack of approved vaccines or curative antiviral therapies.
• Limited healthcare infrastructure in rural and endemic regions.
• High fatality rates in severe cases, especially among pregnant women.
• Underreporting and misdiagnosis due to symptom overlap with malaria and other febrile illnesses.
• Supply chain challenges for diagnostics and therapeutics during outbreaks.

Opportunities
• Ongoing clinical trials for Lassa fever vaccines (platforms include recombinant vectors, DNA, and mRNA).
• Development of monoclonal antibody therapies showing promise in early-stage trials.
• Expansion of point-of-care rapid diagnostic tests enabling early detection.
• Growth of public-private partnerships for epidemic preparedness.
• Integration of rodent-control and community health education programs to reduce transmission.

Market Growth Outlook (2024-2034)
The Lassa Fever Market will increase from USD 78 million in 2024 to USD 165 million by 2034, driven by rising outbreak preparedness, accelerated vaccine development, and enhanced diagnostic capabilities.
Emergency response capacity building and sustainable surveillance infrastructure are expected to be the biggest growth enablers.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71747/lassa-fever-market

Segmentation Analysis
By Treatment Type
Antiviral Therapies:
• Ribavirin remains the primary treatment used for early-stage Lassa fever, though efficacy depends on early administration.
• Novel small-molecule antivirals targeting viral replication pathways are under development.
Supportive & Critical Care:
• Fluid management, electrolyte correction, and treatment of shock and organ failure.
• Advanced care required for severe hemorrhagic cases.
Monoclonal Antibody Therapies:
• Under active development with promising preclinical and clinical trial results.
By Diagnosis
• RT-PCR Testing for viral RNA detection remains the gold standard.
• ELISA Tests for antigen and IgM antibody detection.
• Rapid Diagnostic Tests (RDTs) emerging for low-resource settings.
• Viral Isolation used in high-containment laboratories for research.

By End User
• Hospitals & Isolation Centers manage severe and hospitalized cases.
• Public Health Laboratories perform PCR and serological testing.
• NGOs & Global Health Agencies support outbreak response and surveillance.
• Research Institutions lead vaccine and antiviral development efforts.

Regional Insights
West Africa (Primary Endemic Region)
West Africa remains the epicenter of Lassa fever, accounting for the majority of global cases. Nigeria experiences the highest case burden, followed by Sierra Leone, Liberia, Guinea, and parts of Benin. Increased diagnostic capacity and awareness campaigns are improving detection and reporting.
North America & Europe
These regions contribute primarily through research funding, vaccine development, and surveillance support. Several biotech firms in the U.S. and Europe are actively working on Lassa fever vaccine candidates.
Asia Pacific
Minimal disease burden, but growing interest in vaccine procurement strategies for pandemic preparedness.
Latin America & Middle East/Africa (Non-Endemic Regions)
Limited cases, mostly travel-associated, but improved surveillance is enhancing early detection capabilities.

Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71747

Competitive Landscape
The Lassa fever market includes antiviral drug developers, vaccine researchers, diagnostic companies, and global health partners.
Key Entities Include:
• IAVI
• CEPI
• Emergent BioSolutions
• Moderna (mRNA platforms)
• Inovio Pharmaceuticals
• Zalgen Labs (antibody development)
• Soligenix
• Mapp Biopharmaceutical
• Thermo Fisher Scientific (diagnostics)
These organizations focus on vaccines, rapid diagnostics, monoclonal antibodies, antiviral drug discovery, and outbreak management tools.

Recent Developments
• Acceleration of Lassa fever vaccine candidates under CEPI's epidemic preparedness program.
• Promising early results from monoclonal antibody cocktails targeting the Lassa virus glycoprotein.
• Expansion of PCR testing hubs in West Africa to strengthen outbreak detection.
• Increased deployment of community-level rapid diagnostic tools.
• Growth of global partnerships aimed at integrated rodent control, sanitation, and education programs.

This report is also available in the following languages : Japanese (ラッサ熱市場), Korean (라사 열병 시장), Chinese (拉沙热市场), French (Marché de la fièvre de Lassa), German (Lassa-Fieber-Markt), and Italian (Mercato della febbre di Lassa), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71747

Our More Reports:

Generalized Myasthenia Gravis (gMG) Market
https://exactitudeconsultancy.com/reports/72089/generalized-myasthenia-gravis-gmg-market

Lennox Gastaut Syndrome Market
https://exactitudeconsultancy.com/reports/72091/lennox-gastaut-syndrome-market

Neuromyelitis optica spectrum disorder (NMOSD) Market
https://exactitudeconsultancy.com/reports/72093/neuromyelitis-optica-spectrum-disorder-nmosd-market

Spinocerebellar Ataxia (SCA) Market
https://exactitudeconsultancy.com/reports/72095/spinocerebellar-ataxia-sca-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.